Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165878 | 0.93 | KDM4E (0.47) | KDM4EPKMRORCGPR119HDAC1 | |
| SCHEMBL4166376 | 0.84 | GPR119 (0.53) | GPR119HPGDFAAH | |
| SCHEMBL4169160 | 0.81 | GPR119 (0.46) | GPR119HPGDHDAC1FAAH | |
| SCHEMBL4165880 | 0.77 | GPR119 (0.53) | GPR119FAAH | |
| SCHEMBL2143374 | 0.76 | ALDH1A1 (0.57) | GPR119HPGDNPC1USP2ALDH1A1 | |
| SCHEMBL4161504 | 0.75 | GPR119 (0.46) | GPR119FAAH | |
| SCHEMBL4157433 | 0.73 | GPR119 (0.46) | KDM4EPKMGPR119FAAH | |
| SCHEMBL4492635 | 0.72 | KDM4E (0.53) | KDM4EPKMGPR119 | |
| SCHEMBL4001752 | 0.72 | PRPS1 (0.53) | KDM4EPKMGPR119FAAH | |
| SCHEMBL6112673 | 0.72 | NAMPT (0.54) | HPGDNPC1ALDH1A1RAB9ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084466-B2 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-27 | — | — | US | disclosed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | HRH4, HRH3, HRH1 | KDM4E 1407/4885PKM 4484/4885RORC 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.